首页 > 最新文献

European Heart Journal Supplements最新文献

英文 中文
The development of a free and user-friendly health education website targeting Egyptians with cardiovascular diseases 为患有心血管疾病的埃及人开发一个免费和用户友好的健康教育网站
4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-09-01 DOI: 10.1093/eurheartjsupp/suad113.016
Mohamed El-Khatib, Mahmoud Eltayyeb, Nevin Mohamed, Saber Mostafa
Abstract Background Health care provider’s patient education promotes patients’ comprehension and adherence to medical instructions, hence improving patient health. Various obstacles exist in providing successful patient education to patients with multiple chronic diseases, such as providing the appropriate time, variety, and types of learning materials, as well as assessing the level of comprehension. To assist in overcoming these obstacles, it is essential to investigate new electronic tools for patient education, such as mobile devices, interactive media, and multimedia educational content in healthcare facilities. Aim Determine the steps that need to be taken to develop a user-friendly, cost-free website for health education. Process and Steps Create a specialized team to manage the process of creating educational resources and a website; in MYF, the team comprised of nurses who moderate the website, create the leaflets and films, and an external supporter who edited and directed the videos. Choose the appropriate website and design templates. The MYF nurses use (Google Site), which is a free, easy-to-use website design tool, and for leaflets, the team uses (Ai illustrator), which is an easy-to-use software application for writing, sketching, and adding attractive images. Identify the patient education needs based on patient-centeredness and the most prevalent cardiac diseases, procedures, and preventative measures via the educational council. The offered leaflets are written in Arabic and English. The videos presented have Arabic voiceovers and subtitles. Using the most up-to-date evidence-based resources, identify the appropriate evidence-based resources. Determine the appropriate presenting techniques using electronic leaflets and educational videos. Materials design, including leaflet and video design, script, and voiceover development. Revision of instructional materials through the educational council. Following admission to the hospital, the nurses in charge conduct a health awareness session about the health education website and provide the link/QR code for accessing the website after discharge. Challenges Patients have barriers to using the free website due to economic circumstances and tocology illiteracy, such as a lack of access to a cellphone or internet, or an inability to utilise the associated technology. Additionally, MYF provide printed materials or invent other family members who can access the website for. Conclusion Clinicians can reduce patient apprehension and confusion and enhance the related knowledge by directing them to credible, up-to-date, and comprehensible sources of knowledge provided on a user-friendly health education website on a variety of internet platforms is regarded as a valuable cost-effective and expense-reduction strategy. Recommendation Health care facilities should develop free and user-friendly educational websites which will enhance patient knowledge and awareness.
摘要背景医护人员对患者的教育可以促进患者对医嘱的理解和遵守,从而改善患者的健康状况。在向患有多种慢性疾病的患者提供成功的患者教育方面存在各种障碍,例如提供适当的时间、种类和类型的学习材料,以及评估理解水平。为了帮助克服这些障碍,必须研究用于患者教育的新电子工具,例如医疗机构中的移动设备、互动媒体和多媒体教育内容。目的确定需要采取的步骤,以建立一个用户友好、免费的健康教育网站。创建一个专门的团队来管理创建教育资源和网站的过程;在MYF,团队由护士组成,他们负责管理网站、制作传单和影片,还有一名外部支持者负责编辑和指导视频。选择合适的网站和设计模板。MYF护士使用(Google Site),这是一个免费的、易于使用的网站设计工具,而该团队使用(Ai illustrator)制作传单,这是一个易于使用的软件应用程序,用于写作、素描和添加吸引人的图像。通过教育委员会,根据以患者为中心和最流行的心脏病、手术和预防措施,确定患者教育需求。提供的传单是用阿拉伯语和英语写的。所提供的视频有阿拉伯语画外音和字幕。使用最新的循证资源,确定适当的循证资源。使用电子宣传单和教育视频确定适当的展示技巧。材料设计,包括传单和视频设计,剧本和画外音的开发。通过教育委员会修订教学材料。入院后,主管护士对健康教育网站进行健康宣讲会,并提供出院后访问网站的链接/二维码。由于经济环境和技术文盲,患者在使用免费网站方面存在障碍,例如无法使用手机或互联网,或无法利用相关技术。此外,MYF提供印刷材料或发明其他可以访问网站的家庭成员。结论临床医生可以通过引导患者使用各种互联网平台上的用户友好的健康教育网站提供的可靠、最新和可理解的知识来源,减少患者的忧虑和困惑,并提高相关知识的水平,这是一种有价值的成本效益和降低费用的策略。卫生保健机构应开发免费和用户友好的教育网站,以提高患者的知识和意识。
{"title":"The development of a free and user-friendly health education website targeting Egyptians with cardiovascular diseases","authors":"Mohamed El-Khatib, Mahmoud Eltayyeb, Nevin Mohamed, Saber Mostafa","doi":"10.1093/eurheartjsupp/suad113.016","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suad113.016","url":null,"abstract":"Abstract Background Health care provider’s patient education promotes patients’ comprehension and adherence to medical instructions, hence improving patient health. Various obstacles exist in providing successful patient education to patients with multiple chronic diseases, such as providing the appropriate time, variety, and types of learning materials, as well as assessing the level of comprehension. To assist in overcoming these obstacles, it is essential to investigate new electronic tools for patient education, such as mobile devices, interactive media, and multimedia educational content in healthcare facilities. Aim Determine the steps that need to be taken to develop a user-friendly, cost-free website for health education. Process and Steps Create a specialized team to manage the process of creating educational resources and a website; in MYF, the team comprised of nurses who moderate the website, create the leaflets and films, and an external supporter who edited and directed the videos. Choose the appropriate website and design templates. The MYF nurses use (Google Site), which is a free, easy-to-use website design tool, and for leaflets, the team uses (Ai illustrator), which is an easy-to-use software application for writing, sketching, and adding attractive images. Identify the patient education needs based on patient-centeredness and the most prevalent cardiac diseases, procedures, and preventative measures via the educational council. The offered leaflets are written in Arabic and English. The videos presented have Arabic voiceovers and subtitles. Using the most up-to-date evidence-based resources, identify the appropriate evidence-based resources. Determine the appropriate presenting techniques using electronic leaflets and educational videos. Materials design, including leaflet and video design, script, and voiceover development. Revision of instructional materials through the educational council. Following admission to the hospital, the nurses in charge conduct a health awareness session about the health education website and provide the link/QR code for accessing the website after discharge. Challenges Patients have barriers to using the free website due to economic circumstances and tocology illiteracy, such as a lack of access to a cellphone or internet, or an inability to utilise the associated technology. Additionally, MYF provide printed materials or invent other family members who can access the website for. Conclusion Clinicians can reduce patient apprehension and confusion and enhance the related knowledge by directing them to credible, up-to-date, and comprehensible sources of knowledge provided on a user-friendly health education website on a variety of internet platforms is regarded as a valuable cost-effective and expense-reduction strategy. Recommendation Health care facilities should develop free and user-friendly educational websites which will enhance patient knowledge and awareness.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135298867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of residual SYNTAX score to predict clinical outcome after acute myocardial infarction 残差SYNTAX评分预测急性心肌梗死后临床预后的效用
4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-09-01 DOI: 10.1093/eurheartjsupp/suad113.017
Ahmad Samir, Mai Elshinawi, Hesham Yehia, Mohamed Mahjouri, Mohamed Elhafy, Ahmed Shehata, Bassem Zarif, Azza Farrag
Abstract Aims Acute myocardial infarction (AMI) represents a huge health burden and a growing economical challenge, particularly with recurrent major adverse cardiovascular events (MACE). Large attention is critically mandated to identify population at higher risk for recurrent MACE to maximize secondary preventive measures. This study aimed to evaluate the utility of residual SYNTAX Score (RSS) after percutaneous coronary intervention (PCI) to the culprit vessel(s) in patients with AMI (STEMI or NSTEMI) to predict 6-months clinical outcomes. Methods and results A total of 492 eligible AMI patients were recruited through a period of 12 months. The RSS was systematically calculated after the PCI procedures. Median RSS was 4 (minimum 0–maximum 47.5). RSS showed excellent association to mid-term clinical outcomes. At cut-off value of RSS 3 had robust prediction for subsequent heart failure (HF), recurrent AMI, unplanned revascularization and the composite of MACE (P < 0.001). A significantly higher RSS was found in those who developed heart failure through the 6-months follow up period compared to those who did not (10 vs. 3, P < 0.001). Similar significant difference was found for recurrent ACS (11.5 vs. 3, P < 0.001), unplanned revascularization (15 vs. 3, P < 0.001) and occurrence of MACE (12 vs. 3, P < 0.001). Conclusions RSS is a sensitive predictor for 6-months adverse clinical outcomes after AMI. Calculating RSS at the end of PCI can guide intensification of secondary preventive measures. Ability of RSS- tailored management to impact clinical outcomes in high-risk patients is to be evaluated.Improvement, with subsequent amelioration of LV diastolic function. The Dapa group had a significantly greater improvement in LVEF at four months and six months compared to the Empa group. While the Empa group showed a significant improvement in HbA1C at six months compared to the Dapa group. Additional Content An author video to accompany this abstract is available on https://academic.oup.com/eurheartjsupp. Please click on the arrow next to ‘More Content’ and then click on ‘Author videos’.
摘要目的急性心肌梗死(AMI)是一个巨大的健康负担和日益增长的经济挑战,特别是复发性主要不良心血管事件(MACE)。必须高度重视确定复发性MACE风险较高的人群,以最大限度地采取二级预防措施。本研究旨在评估AMI (STEMI或NSTEMI)患者经皮冠状动脉介入治疗(PCI)后残留SYNTAX评分(RSS)对罪魁祸首血管的效用,以预测6个月的临床结果。方法和结果在12个月的时间里,共招募了492名符合条件的AMI患者。系统计算PCI术后的相对过饱和度。中位RSS为4(最小0 -最大47.5)。RSS与中期临床结果有很好的相关性。在截断值处,rss3对随后的心力衰竭(HF)、复发性AMI、计划外血运重建术和MACE复合有较强的预测作用(P <0.001)。在6个月的随访期间,发生心力衰竭的患者的相对过饱和度明显高于未发生心力衰竭的患者(10比3,P <0.001)。在复发性ACS中也发现了类似的显著差异(11.5 vs. 3, P <0.001),计划外血运重建术(15 vs. 3, P <0.001)和MACE的发生(12 vs. 3, P <0.001)。结论相对过饱和度是急性心肌梗死后6个月不良临床结局的敏感预测指标。在PCI结束时计算RSS可以指导二级预防措施的加强。在高危患者中,RSS量身定制的管理对临床结果影响的能力有待评估。改善,随后左室舒张功能改善。与Empa组相比,Dapa组在4个月和6个月时的LVEF有明显更大的改善。与Dapa组相比,Empa组在6个月时的HbA1C有显著改善。一个作者的视频,伴随着这个摘要可在https://academic.oup.com/eurheartjsupp。请点击“更多内容”旁边的箭头,然后点击“作者视频”。
{"title":"Utility of residual SYNTAX score to predict clinical outcome after acute myocardial infarction","authors":"Ahmad Samir, Mai Elshinawi, Hesham Yehia, Mohamed Mahjouri, Mohamed Elhafy, Ahmed Shehata, Bassem Zarif, Azza Farrag","doi":"10.1093/eurheartjsupp/suad113.017","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suad113.017","url":null,"abstract":"Abstract Aims Acute myocardial infarction (AMI) represents a huge health burden and a growing economical challenge, particularly with recurrent major adverse cardiovascular events (MACE). Large attention is critically mandated to identify population at higher risk for recurrent MACE to maximize secondary preventive measures. This study aimed to evaluate the utility of residual SYNTAX Score (RSS) after percutaneous coronary intervention (PCI) to the culprit vessel(s) in patients with AMI (STEMI or NSTEMI) to predict 6-months clinical outcomes. Methods and results A total of 492 eligible AMI patients were recruited through a period of 12 months. The RSS was systematically calculated after the PCI procedures. Median RSS was 4 (minimum 0–maximum 47.5). RSS showed excellent association to mid-term clinical outcomes. At cut-off value of RSS 3 had robust prediction for subsequent heart failure (HF), recurrent AMI, unplanned revascularization and the composite of MACE (P &amp;lt; 0.001). A significantly higher RSS was found in those who developed heart failure through the 6-months follow up period compared to those who did not (10 vs. 3, P &amp;lt; 0.001). Similar significant difference was found for recurrent ACS (11.5 vs. 3, P &amp;lt; 0.001), unplanned revascularization (15 vs. 3, P &amp;lt; 0.001) and occurrence of MACE (12 vs. 3, P &amp;lt; 0.001). Conclusions RSS is a sensitive predictor for 6-months adverse clinical outcomes after AMI. Calculating RSS at the end of PCI can guide intensification of secondary preventive measures. Ability of RSS- tailored management to impact clinical outcomes in high-risk patients is to be evaluated.Improvement, with subsequent amelioration of LV diastolic function. The Dapa group had a significantly greater improvement in LVEF at four months and six months compared to the Empa group. While the Empa group showed a significant improvement in HbA1C at six months compared to the Dapa group. Additional Content An author video to accompany this abstract is available on https://academic.oup.com/eurheartjsupp. Please click on the arrow next to ‘More Content’ and then click on ‘Author videos’.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135298875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Newly Approved Medications Sacubitril/Valsartan, Empagliflozin and Dapagliflozin on the Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction 新批准的药物苏比利/缬沙坦、恩格列净和达格列净对心力衰竭伴射血分数降低患者生活质量的影响
4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-09-01 DOI: 10.1093/eurheartjsupp/suad113.005
Amr Setouhi, Asmaa Taha, Hazem M A Farrag, Hany T Asklany
ABSTRACT Background Per the guidelines established by the European Society of Cardiology (ESC) guidelines for diagnosing and managing chronic and acute heart failure, Sacubitril/Valsartan, Empagliflozin, and Dapagliflozin are suggested to replace an angiotensin-converting enzyme (ACE) inhibitor to significantly minimize the heart failure (HF) associated risks including hospitalization and possible death of HF ambulatory patients with reduced ejection fraction that remain symptomatic. Objective This work aimed to evaluate the health-related quality of life (HRQOL) changes in HFrEF patients throughout treatment with newly approved medications sacubitril/valsartan, Dapagliflozin, and empagliflozin using Minnesota living with heart failure questionnaire (MLHFQ) and Kansas City Cardiomyopathy Questionnaire (KCCQ) -12 at baseline, 3 months, and 6 months of treatment. Methods This prospective study was conducted on 500 patients with chronic HF with 35% or less LVEF, New York Heart Association class III or IV symptoms who visited Minia university cardiothorasic hospital, cardiology outpatient clinic from period of March 2022 to May 2023. Patients were treated using maximum tolerated doses of guideline-directed medical therapy; angiotensin-converting enzyme inhibitors (ACEIs), ß-blocker (BB), mineralocorticoid receptor antagonist (MRA), and systolic blood pressure greater than 105 mmHg. A total of 3 visits were done (baseline visit, months 3 and 6). At the baseline visit, patients were on ACEIs, BB, MRA, and diuretics and quality of life (QOL) was assessed for this regimen by MLHFQ and KCCQ.12 Then dapagliflozin or empagliflozin was added to the previous regimen, and a reevaluation of patients' QOL was done at 3 months. The ACEI or ARBs was replaced by sacubitril/valsartan, and the reevaluation of QOL was evaluated at 6 months. Results Systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), E/e′ ratio, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were remarkably decreased at 6 months compared to baseline (P value &lt;0.001), at 6 months compared to 3 months (P value &lt;0.001), and at 3 months compared to baseline (P value &lt;0.001). Left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), and potassium were significantly increased at 6 months compared to baseline (P value &lt;0.001), at 6 months compared to 3 months (P value &lt;0.001), and at 3 months compared to baseline (P value &lt;0.001). MLHFQ and KCCQ-23 scores were significantly improved at 6 months compared to baseline (P value &lt;0.001), compared to 3 months (P value &lt;0.001), and at 3 months compared to baseline (P value &lt;0.001). 28 (5.6%) patients had stopped the medications due to adverse events (AEs). Conclusions Treatment of HFrEF patients with sodium-glucose Co-transporter-2 inhibitors (SGLT2i) and/or sacubitril/val
背景:根据欧洲心脏病学会(ESC)制定的慢性和急性心力衰竭诊断和管理指南,建议Sacubitril/Valsartan、Empagliflozin和Dapagliflozin替代血管紧张素转换酶(ACE)抑制剂,以显著降低心力衰竭(HF)相关风险,包括住院和可能死亡的射血分数降低的HF门诊患者仍有症状。本研究旨在评估HFrEF患者在接受新批准的药物sacubitril/缬沙坦、Dapagliflozin和empagliflozin治疗过程中与健康相关的生活质量(HRQOL)的变化,采用明尼苏达州心衰生活问卷(MLHFQ)和堪萨斯城心肌病问卷(KCCQ) -12,分别在基线、治疗3个月和6个月。方法对2022年3月至2023年5月在Minia大学心胸医院心内科门诊就诊的500例LVEF 35%及以下、纽约心脏协会III级或IV级症状的慢性HF患者进行前瞻性研究。患者使用最大耐受剂量的指导药物治疗;血管紧张素转换酶抑制剂(ACEIs), ß-阻滞剂(BB),矿皮质激素受体拮抗剂(MRA),收缩压大于105 mmHg。总共进行了3次访问(基线访问,第3个月和第6个月)。基线访问时,患者使用ACEIs, BB, MRA和利尿剂,并通过MLHFQ和kccq评估该方案的生活质量(QOL)。12然后在先前方案中添加达格列净或恩格列净,并在3个月时重新评估患者的QOL。用苏比里尔/缬沙坦替代ACEI或arb, 6个月时重新评估生活质量。结果6个月时收缩压(SBP)、舒张压(DBP)、左室舒张末期容积(LVEDV)、左室收缩末期容积(LVESV)、E/ E′比、n -末端前b型利钠肽(NT-proBNP)与基线相比显著降低(P值<0.001), 6个月时与3个月时(P值<0.001), 3个月时与基线相比(P值<0.001)。左心室射血分数(LVEF)、整体纵向应变(GLS)和钾在6个月时与基线相比显著增加(P值<0.001),在6个月时与3个月时相比(P值<0.001),在3个月时与基线相比(P值<0.001)。与基线相比,MLHFQ和KCCQ-23评分在6个月时显著改善(P值<0.001),与3个月时相比(P值<0.001),与3个月时相比(P值<0.001)。28例(5.6%)患者因不良事件(ae)停药。结论根据KCCQ和MLHFQ评分,使用钠-葡萄糖共转运蛋白-2抑制剂(SGLT2i)和/或苏比里尔/缬沙坦治疗HFrEF患者可快速显著改善患者的生活质量。
{"title":"Effect of Newly Approved Medications Sacubitril/Valsartan, Empagliflozin and Dapagliflozin on the Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction","authors":"Amr Setouhi, Asmaa Taha, Hazem M A Farrag, Hany T Asklany","doi":"10.1093/eurheartjsupp/suad113.005","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suad113.005","url":null,"abstract":"ABSTRACT Background Per the guidelines established by the European Society of Cardiology (ESC) guidelines for diagnosing and managing chronic and acute heart failure, Sacubitril/Valsartan, Empagliflozin, and Dapagliflozin are suggested to replace an angiotensin-converting enzyme (ACE) inhibitor to significantly minimize the heart failure (HF) associated risks including hospitalization and possible death of HF ambulatory patients with reduced ejection fraction that remain symptomatic. Objective This work aimed to evaluate the health-related quality of life (HRQOL) changes in HFrEF patients throughout treatment with newly approved medications sacubitril/valsartan, Dapagliflozin, and empagliflozin using Minnesota living with heart failure questionnaire (MLHFQ) and Kansas City Cardiomyopathy Questionnaire (KCCQ) -12 at baseline, 3 months, and 6 months of treatment. Methods This prospective study was conducted on 500 patients with chronic HF with 35% or less LVEF, New York Heart Association class III or IV symptoms who visited Minia university cardiothorasic hospital, cardiology outpatient clinic from period of March 2022 to May 2023. Patients were treated using maximum tolerated doses of guideline-directed medical therapy; angiotensin-converting enzyme inhibitors (ACEIs), ß-blocker (BB), mineralocorticoid receptor antagonist (MRA), and systolic blood pressure greater than 105 mmHg. A total of 3 visits were done (baseline visit, months 3 and 6). At the baseline visit, patients were on ACEIs, BB, MRA, and diuretics and quality of life (QOL) was assessed for this regimen by MLHFQ and KCCQ.12 Then dapagliflozin or empagliflozin was added to the previous regimen, and a reevaluation of patients' QOL was done at 3 months. The ACEI or ARBs was replaced by sacubitril/valsartan, and the reevaluation of QOL was evaluated at 6 months. Results Systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), E/e′ ratio, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were remarkably decreased at 6 months compared to baseline (P value &amp;lt;0.001), at 6 months compared to 3 months (P value &amp;lt;0.001), and at 3 months compared to baseline (P value &amp;lt;0.001). Left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), and potassium were significantly increased at 6 months compared to baseline (P value &amp;lt;0.001), at 6 months compared to 3 months (P value &amp;lt;0.001), and at 3 months compared to baseline (P value &amp;lt;0.001). MLHFQ and KCCQ-23 scores were significantly improved at 6 months compared to baseline (P value &amp;lt;0.001), compared to 3 months (P value &amp;lt;0.001), and at 3 months compared to baseline (P value &amp;lt;0.001). 28 (5.6%) patients had stopped the medications due to adverse events (AEs). Conclusions Treatment of HFrEF patients with sodium-glucose Co-transporter-2 inhibitors (SGLT2i) and/or sacubitril/val","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135298361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Moodle as online platform for cardiac nurses’ competency: nursing staff experiences Moodle作为心脏护士胜任力在线平台:护理人员经验
4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-09-01 DOI: 10.1093/eurheartjsupp/suad113.011
Mohamed El-Khatib, Ibrahim Helmy, Mahmoud Eltayyeb
Abstract Background Aswan Heart Centre competency project were started in 2017, nurse’s competency were tillered and implemented within the nursing units. Self-assessment and preceptor grading ideationally to constrictive comment should be documented in the competency tool for every staff, was no unified way to keep tracking these documentations and very hard to secure the hard copy. Aim Is to establish an online platform where the competencies are accessible and high secured that also controls and facilitates the use of nursing competencies. Process Moodle as a cloud-based learning management system (LMS) selected to be the new Online competency platform. Moodle expert were contacted by the nursing education department to assist and support the process. Online could server to host and upload the platform were established by the information technology department. After competencies and users uploaded pilot phase were started to identify the gap in the Moodle platform. After 4 months of use survey were conducted to get a clear view from the staff. Data analysis Most of the staff were satisfied about Moodle use, but the form still need farther support from the information technology department to host the Moodle cloud in stable server to avoid the browser render. Recommendation The use of cloud-based learning management system like Moodle will maintain the easy accessibility and the high security of the data also will facilitate the data audit for further plans.
背景阿斯旺心脏中心胜任力项目于2017年启动,对护士胜任力进行分类并在护理单位内实施。每个工作人员的能力工具中都应该记录自我评估和导师的等级评定以及限制性评论,没有统一的方法来跟踪这些文件,并且很难确保硬拷贝的安全。目的是建立一个在线平台,其中能力是可访问的和高度安全的,也控制和促进护理能力的使用。过程Moodle作为一个基于云的学习管理系统(LMS)被选为新的在线能力平台。护理教育部门联系了Moodle专家来协助和支持这一过程。在线可服务器托管和上传平台由信息技术部门建立。在能力和用户上传试验阶段之后,开始识别Moodle平台的差距。使用4个月后进行调查,以获得员工的清晰看法。大多数员工对Moodle的使用感到满意,但是表单还需要信息技术部门的进一步支持,将Moodle云托管在稳定的服务器上,以避免浏览器渲染。使用Moodle等基于云的学习管理系统,可以保持数据的易访问性和高安全性,也便于后续计划的数据审计。
{"title":"Moodle as online platform for cardiac nurses’ competency: nursing staff experiences","authors":"Mohamed El-Khatib, Ibrahim Helmy, Mahmoud Eltayyeb","doi":"10.1093/eurheartjsupp/suad113.011","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suad113.011","url":null,"abstract":"Abstract Background Aswan Heart Centre competency project were started in 2017, nurse’s competency were tillered and implemented within the nursing units. Self-assessment and preceptor grading ideationally to constrictive comment should be documented in the competency tool for every staff, was no unified way to keep tracking these documentations and very hard to secure the hard copy. Aim Is to establish an online platform where the competencies are accessible and high secured that also controls and facilitates the use of nursing competencies. Process Moodle as a cloud-based learning management system (LMS) selected to be the new Online competency platform. Moodle expert were contacted by the nursing education department to assist and support the process. Online could server to host and upload the platform were established by the information technology department. After competencies and users uploaded pilot phase were started to identify the gap in the Moodle platform. After 4 months of use survey were conducted to get a clear view from the staff. Data analysis Most of the staff were satisfied about Moodle use, but the form still need farther support from the information technology department to host the Moodle cloud in stable server to avoid the browser render. Recommendation The use of cloud-based learning management system like Moodle will maintain the easy accessibility and the high security of the data also will facilitate the data audit for further plans.","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135299075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of left atrial function by two-dimensional speckle tracking echocardiography in patients with cryptogenic stroke 二维散斑跟踪超声心动图评价隐源性脑卒中患者左心房功能
4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-09-01 DOI: 10.1093/eurheartjsupp/suad113.007
Amr Setouhi, Ahmed M Ali, Tarek A Rahman, Mohamed A Kader A. Wahab
Abstract Cryptogenic cerebro-vascular stroke is defined as ischemic stroke without definite etiology in spite of complete work up. It differs from embolic stroke of undetermined source (ESUS) which is a subgroup including the cardio-embolic sources.We aimed to evaluate the left atrial function using two-dimensional speckle tracking echocardiography (2D-STE) as a possible cause for cryptogenic stroke or a predictor for subclinical AF.TEE has an important role in the work up of cryptogenic stroke and ESUS searching for a possible cardio-embolic source including PFO, left atrial appendage thrombi and atheromatous plaques in aortic arch. Patients and methods Our retrospective cohort study included 62 patients of both sexes with unexplained cerebro-vascular stroke or TIA in stroke unit of Minia University.After performing TEE, 22 patients were excluded as they were proven to have a possible source for cardio-embolism.So, Participants were divided into two groups, group I which included 40 patients with cryptogenic stroke and group II which included 40 healthy participants with no medical history of significance as a control group.Two-dimensional trans-thoracic echocardiography and speckle tracking echocardiography were performed in both groups. We used LA diameter in PLAX, LA volume index (LAVI), LA ejection fraction (LAEF), LA strain rate during reservoir phase (LASr) and LV diastolic dysfunction as parameters of LA dysfunction.48 hours ECG rhythm monitoring during hospitalization was used in participants of group I for detection of more than 30 s episodes of subclinical or paroxysmal atrial fibrillation.Bilateral carotid duplex ultrasonography was also performed for exclusion of significant carotid artery stenosis as a possible cause for stroke. Results The parameters of LA dysfunction were significantly affected in group I than group II with P-value &lt; 0.0001 for LV diastolic dysfunction, LAVI, LAEF and LASr, and 0.001 for LA diameter in PLAX. Episodes of AF were noticed in 14 patients of group I (group Ia, 35%) and the other 26 patients were called (group Ib, 65%).We compared LA dysfunction parameters in Group Ib and group II (healthy controls). There was significant affection of LV diastolic dysfunction in group Ib than group II with P-value &lt; 0.011. LAVI, LAEF and LASr were significantly affected in group Ib than group II with P-value &lt; 0.0001. While, there is no significant difference in LA diameter between both groups with P-value = 0.053.We found that left atrial strain rate during reservoir phase (LASr) is the most sensitive and specific parameter of left atrial cardiopathy in prediction of AF with cut-off point ≤24.5 % and P-value &lt; 0.0001, then LAEF with cut-off point ≤40.5 % and P-value = 0.011. The LAVI is the least sensitive and specific parameter with cut-off point ≥38.5 ml/m2 and P-value = 0.003. Conclusion 2D-STE has an important role in the evaluation of LA dysfunction as a possible cause for cryptogenic s
隐源性脑血管卒中被定义为没有明确病因的缺血性卒中,尽管有完整的研究。它不同于来源不明的栓塞性卒中(ESUS),后者是包括心源性栓塞在内的一个亚组。我们的目的是利用二维斑点跟踪超声心动图(2D-STE)评估左心房功能,作为隐源性卒中的可能原因或亚临床房颤的预测因子。tee在隐源性卒中和ESUS寻找可能的心脏栓塞源(包括PFO、左心房附件血栓和主动脉弓动脉粥样硬化斑块)的工作中发挥重要作用。患者与方法回顾性队列研究纳入Minia大学脑卒中科室不明原因脑血管卒中或TIA患者62例。在进行TEE治疗后,22名患者被排除在外,因为他们被证明可能有心脏栓塞的来源。因此,参与者被分为两组,第一组包括40名隐源性卒中患者,第二组包括40名健康参与者,没有明显的病史作为对照组。两组均行二维经胸超声心动图和斑点跟踪超声心动图检查。我们以PLAX的LA直径、LA容积指数(LAVI)、LA射血分数(LAEF)、储层期LA应变率(LASr)和左室舒张功能障碍作为LA功能障碍的参数。第一组患者住院期间48小时心电图节律监测,用于检测30次以上亚临床或阵发性心房颤动。同时进行双侧颈动脉双工超声检查,排除可能导致卒中的颈动脉明显狭窄。结果I组LA功能障碍参数明显高于II组,p值<左室舒张功能障碍、LAVI、LAEF和LASr为0.0001,PLAX的左室直径为0.001。I组14例(Ia组,35%)出现房颤发作,Ib组26例(65%)出现房颤发作。我们比较了Ib组和II组(健康对照)的LA功能障碍参数。Ib组左室舒张功能不全较II组有显著差异,p值<0.011. Ib组LAVI、LAEF、LASr均显著高于II组,p值<0.0001. 两组间LA直径差异无统计学意义,p值= 0.053。我们发现储液期左房应变率(LASr)是预测房颤最敏感、最特异的参数,截断点≤24.5%,p值<0.0001,则LAEF截断点≤40.5%,p值= 0.011。LAVI是最不敏感和特异性的参数,截断点≥38.5 ml/m2, p值= 0.003。结论2D-STE在评估TEE术后LA功能障碍是否可能导致隐源性卒中以及排除可能的心脏栓塞来源方面具有重要作用。LAEF和LAVI作为LA功能障碍的重要参数和AF的预测指标,但其敏感性和特异性低于LASr。LAEF和LAVI作为LA功能障碍的重要参数和AF的预测指标。
{"title":"Evaluation of left atrial function by two-dimensional speckle tracking echocardiography in patients with cryptogenic stroke","authors":"Amr Setouhi, Ahmed M Ali, Tarek A Rahman, Mohamed A Kader A. Wahab","doi":"10.1093/eurheartjsupp/suad113.007","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suad113.007","url":null,"abstract":"Abstract Cryptogenic cerebro-vascular stroke is defined as ischemic stroke without definite etiology in spite of complete work up. It differs from embolic stroke of undetermined source (ESUS) which is a subgroup including the cardio-embolic sources.We aimed to evaluate the left atrial function using two-dimensional speckle tracking echocardiography (2D-STE) as a possible cause for cryptogenic stroke or a predictor for subclinical AF.TEE has an important role in the work up of cryptogenic stroke and ESUS searching for a possible cardio-embolic source including PFO, left atrial appendage thrombi and atheromatous plaques in aortic arch. Patients and methods Our retrospective cohort study included 62 patients of both sexes with unexplained cerebro-vascular stroke or TIA in stroke unit of Minia University.After performing TEE, 22 patients were excluded as they were proven to have a possible source for cardio-embolism.So, Participants were divided into two groups, group I which included 40 patients with cryptogenic stroke and group II which included 40 healthy participants with no medical history of significance as a control group.Two-dimensional trans-thoracic echocardiography and speckle tracking echocardiography were performed in both groups. We used LA diameter in PLAX, LA volume index (LAVI), LA ejection fraction (LAEF), LA strain rate during reservoir phase (LASr) and LV diastolic dysfunction as parameters of LA dysfunction.48 hours ECG rhythm monitoring during hospitalization was used in participants of group I for detection of more than 30 s episodes of subclinical or paroxysmal atrial fibrillation.Bilateral carotid duplex ultrasonography was also performed for exclusion of significant carotid artery stenosis as a possible cause for stroke. Results The parameters of LA dysfunction were significantly affected in group I than group II with P-value &amp;lt; 0.0001 for LV diastolic dysfunction, LAVI, LAEF and LASr, and 0.001 for LA diameter in PLAX. Episodes of AF were noticed in 14 patients of group I (group Ia, 35%) and the other 26 patients were called (group Ib, 65%).We compared LA dysfunction parameters in Group Ib and group II (healthy controls). There was significant affection of LV diastolic dysfunction in group Ib than group II with P-value &amp;lt; 0.011. LAVI, LAEF and LASr were significantly affected in group Ib than group II with P-value &amp;lt; 0.0001. While, there is no significant difference in LA diameter between both groups with P-value = 0.053.We found that left atrial strain rate during reservoir phase (LASr) is the most sensitive and specific parameter of left atrial cardiopathy in prediction of AF with cut-off point ≤24.5 % and P-value &amp;lt; 0.0001, then LAEF with cut-off point ≤40.5 % and P-value = 0.011. The LAVI is the least sensitive and specific parameter with cut-off point ≥38.5 ml/m2 and P-value = 0.003. Conclusion 2D-STE has an important role in the evaluation of LA dysfunction as a possible cause for cryptogenic s","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135298220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Cross sectional descriptive study to investigate the different effects of using approved therapeutic regimens options on the quality of life for chronic heart disease patients with reduced ejection fraction 一项横断面描述性研究,旨在探讨使用经批准的治疗方案对射血分数降低的慢性心脏病患者生活质量的不同影响
4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-09-01 DOI: 10.1093/eurheartjsupp/suad113.001
Mohamed Metwally, Enas Abd Elaziz, Rasha Wafaie, Fakhr AlAyoubi, Engy M Emam, Rabab Y Kosba, Ahmed Abd Elaaty
Abstract Aim Investigate the different effects on the quality of life (QOL) between the approved regimens used for Heart failure patients with reduced ejection fraction (HFrEF) treatment in clinical practice. Methods Cross Sectional descriptive study on (HFrEF) patients was conducted from December 2021 to Mars 2023 at governmental and private hospitals in Egypt and Saudi Arabia, the 118 patients were receiving different treatment regimens divided into 4 groups, all groups have B-blockers and mineralocorticoid receptor antagonist (MRA); 1.Conventional therapy group of 33 patients: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARBs), 2. Group of 22 patients: Sacubitril/Valsartan as an angiotensin receptor-neprilysin inhibitor (ARNI), 3. Group of 33 patients (ACEi/ARBs) + Sodium−glucose co-transporter 2 inhibitors (SGLT2i), 4. Group of 30 patients (ARNI) with SGLT2i. Their quality of life assessment was done using validated questionnaire MLHFQ (Minnesota Living with Heart Failure Questionnaire) as face to face interviews and data were collected from hospital records. Statistical software IBM SPSS package version 27.0, a one-way ANOVA test was conducted to compare the difference between 4 groups normally distributed quantitative variables. Post hoc pairwise multiple comparisons were executed using the Tukey HSD test. A multiple linear regression analysis was conducted to assess the ability of the independent variables (Platelets count, Ejection Fraction EF%, Hemoglobin, S.Cr, Gender, WBCs and Urea) to predict the value of MLHFQ score. Significance was judged at the 5% level. Results There was a statistically significant difference In MLHFQ Score for the four groups: F (3, 114) = 8.135, P = 0.000. The actual difference in mean scores was relatively high and this was approved by a large effect size, calculated using eta squared (0.176). Post hoc comparisons indicated that the mean score for Conventional regimen group (M = 68.06, SD = 19.77, CI95% 11.92–38.67, P &lt; 0.05) and SGLT2i containing regimen group (M = 56.88, SD = 22.21, CI95% 0.74–27.48, P = 0.034) both were significantly different from that of ARNI + SGLT2i combination containing regimen group (M = 42.77, SD = 19.04). By comparing the EF% between the 4 groups, There was a statistically significant difference: F (3, 114) = 2.725, P = 0.047. Post hoc comparisons indicated that the mean score for Conventional containing regimen (M = 33, SD = 8.746, CI95% 0.1–10.43, P = 0.044) was significantly different from that of ARNI + SGLT2i combination regimen (M = 27.73, SD = 7.497). The linear regression analysis for variables showed statistical significance (F Change (7,110) = 5.234, P = .000).The statistically significant affected predicted variables are (S.Cr, P = 0.01), (B.urea, P = 0.003), (Hb, P = 0.011), while R2 = 0.25 explained only 25% of the variance in the dependent variable (MLHFQ score). Conclusions The early beginning of ARNI + SGLT2i with B-blocker + MRA
【摘要】目的探讨临床应用于心力衰竭降射血分数(HFrEF)治疗的不同治疗方案对患者生活质量(QOL)的影响。方法采用横断面描述性研究方法,于2021年12月至2023年12月在埃及和沙特阿拉伯的政府和私立医院对(HFrEF)患者进行研究,118例患者接受不同的治疗方案,分为4组,每组均使用b受体阻滞剂和矿皮质激素受体拮抗剂(MRA);1.常规治疗组33例患者:血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂(ACEi/ARBs);22例患者:Sacubitril/缬沙坦作为血管紧张素受体-neprilysin抑制剂(ARNI);33例患者(ACEi/ARBs) +钠-葡萄糖共转运蛋白2抑制剂(SGLT2i), 4。30例SGLT2i患者(ARNI)。他们的生活质量评估采用有效问卷MLHFQ(明尼苏达州心衰患者生活问卷)进行面对面访谈,数据收集自医院记录。统计学软件为IBM SPSS package version 27.0,采用单因素方差分析比较4组正态分布定量变量的差异。事后两两多重比较采用Tukey HSD检验。采用多元线性回归分析评估自变量(血小板计数、射血分数EF%、血红蛋白、S.Cr、性别、白细胞和尿素)对MLHFQ评分的预测能力。在5%的水平上判断显著性。结果四组患者MLHFQ评分差异有统计学意义:F (3,114) = 8.135, P = 0.000。平均得分的实际差异相对较高,使用平方(0.176)计算的大效应量证实了这一点。事后比较显示,常规方案组平均得分(M = 68.06, SD = 19.77, CI95% 11.92-38.67, P <0.05)和含SGLT2i方案组(M = 56.88, SD = 22.21, CI95% 0.74 ~ 27.48, P = 0.034)与ARNI + SGLT2i联合含方案组(M = 42.77, SD = 19.04)比较差异均有统计学意义。比较4组间EF%,差异有统计学意义:F (3,114) = 2.725, P = 0.047。事后比较显示,常规含药方案的平均评分(M = 33, SD = 8.746, CI95% 0.1 ~ 10.43, P = 0.044)与ARNI + SGLT2i联合方案的平均评分(M = 27.73, SD = 7.497)差异有统计学意义。各变量线性回归分析均有统计学意义(F Change (7110) = 5.234, P = 0.000)。有统计学意义的影响预测变量为(S.Cr, P = 0.01)、(B.urea, P = 0.003)、(Hb, P = 0.011),而R2 = 0.25只能解释因变量(MLHFQ评分)25%的方差。结论早期ARNI + SGLT2i伴b受体阻滞剂+ MRA治疗可改善患者的生活质量,并可降低心力衰竭住院率。一个作者的视频,伴随着这个摘要可在https://academic.oup.com/eurheartjsupp。请点击“更多内容”旁边的箭头,然后点击“作者视频”。
{"title":"A Cross sectional descriptive study to investigate the different effects of using approved therapeutic regimens options on the quality of life for chronic heart disease patients with reduced ejection fraction","authors":"Mohamed Metwally, Enas Abd Elaziz, Rasha Wafaie, Fakhr AlAyoubi, Engy M Emam, Rabab Y Kosba, Ahmed Abd Elaaty","doi":"10.1093/eurheartjsupp/suad113.001","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suad113.001","url":null,"abstract":"Abstract Aim Investigate the different effects on the quality of life (QOL) between the approved regimens used for Heart failure patients with reduced ejection fraction (HFrEF) treatment in clinical practice. Methods Cross Sectional descriptive study on (HFrEF) patients was conducted from December 2021 to Mars 2023 at governmental and private hospitals in Egypt and Saudi Arabia, the 118 patients were receiving different treatment regimens divided into 4 groups, all groups have B-blockers and mineralocorticoid receptor antagonist (MRA); 1.Conventional therapy group of 33 patients: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARBs), 2. Group of 22 patients: Sacubitril/Valsartan as an angiotensin receptor-neprilysin inhibitor (ARNI), 3. Group of 33 patients (ACEi/ARBs) + Sodium−glucose co-transporter 2 inhibitors (SGLT2i), 4. Group of 30 patients (ARNI) with SGLT2i. Their quality of life assessment was done using validated questionnaire MLHFQ (Minnesota Living with Heart Failure Questionnaire) as face to face interviews and data were collected from hospital records. Statistical software IBM SPSS package version 27.0, a one-way ANOVA test was conducted to compare the difference between 4 groups normally distributed quantitative variables. Post hoc pairwise multiple comparisons were executed using the Tukey HSD test. A multiple linear regression analysis was conducted to assess the ability of the independent variables (Platelets count, Ejection Fraction EF%, Hemoglobin, S.Cr, Gender, WBCs and Urea) to predict the value of MLHFQ score. Significance was judged at the 5% level. Results There was a statistically significant difference In MLHFQ Score for the four groups: F (3, 114) = 8.135, P = 0.000. The actual difference in mean scores was relatively high and this was approved by a large effect size, calculated using eta squared (0.176). Post hoc comparisons indicated that the mean score for Conventional regimen group (M = 68.06, SD = 19.77, CI95% 11.92–38.67, P &amp;lt; 0.05) and SGLT2i containing regimen group (M = 56.88, SD = 22.21, CI95% 0.74–27.48, P = 0.034) both were significantly different from that of ARNI + SGLT2i combination containing regimen group (M = 42.77, SD = 19.04). By comparing the EF% between the 4 groups, There was a statistically significant difference: F (3, 114) = 2.725, P = 0.047. Post hoc comparisons indicated that the mean score for Conventional containing regimen (M = 33, SD = 8.746, CI95% 0.1–10.43, P = 0.044) was significantly different from that of ARNI + SGLT2i combination regimen (M = 27.73, SD = 7.497). The linear regression analysis for variables showed statistical significance (F Change (7,110) = 5.234, P = .000).The statistically significant affected predicted variables are (S.Cr, P = 0.01), (B.urea, P = 0.003), (Hb, P = 0.011), while R2 = 0.25 explained only 25% of the variance in the dependent variable (MLHFQ score). Conclusions The early beginning of ARNI + SGLT2i with B-blocker + MRA","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"75 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135298539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does speckle tracking transthorasic echocardiography show subtle changes in left ventricular function in patient with heart failure with reduced ejection fraction treated by Sacubitril-Valsartan 斑点跟踪经胸超声心动图是否显示经苏比替-缬沙坦治疗的心力衰竭伴射血分数降低患者左心室功能的细微变化
4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-09-01 DOI: 10.1093/eurheartjsupp/suad113.004
Amr Setouhi, Hazem M A Farrag, Nasser M Taha, Hany T Askalany
Abstract Introduction Pathophysiology of HF involves a maladaptive response during which the (RAAS) is activated. RAAS activation leads to VC, HT, increased aldosterone levels, increased sympathetic tone, and eventually, cardiac remodeling, all of which are detrimental to the progression of the disease. By blocking these maladaptive elements, ACEIs or ARBs play a major role in reducing morbidity and mortality due to HF, Simultaneously, the NP system is also activated, hence the elevated BNP and NT-pro BNP seen in HF exacerbations. This is a Compensatory mechanism that leads to VD, natriuresis and diuresis, lowers BP, lowers sympathetic tone, and reduces aldosterone levels. The NP system works antagonistically to the RAAS and has favorable effects on the pathogenesis of HF NP are broken down by an enzyme called neprilysin and blocking of its action by neprilysin inhibitor prevent the breakdown of NP leading to prolonged duration of the favorable effects of these peptides. Sacubitril/valsartan is a first-in-class medicine that contains a neprilysin (NEP) inhibitor (sacubitril) and (Ang-II) receptor blocker (valsartan). STE is a sensitive tool for assessing ventricular function, even subclinical myocardial alterations that traditional imaging techniques are not able to detect. Sub endocardial function is powered mostly by longitudinal contraction, it is impaired earlier than circumferential or radial component's. Therefore, Longitudinal function is in most cases the best early marker of LV dysfunction. Objective The aim of our study is to retrospectively detect if the patients treated by sacubitril/valsartan showed no improvement in LVEF assessed by TTE, is the same patient will shows improvement in LVEF assessed by 2D STE? Methods Our study will include 200 patients with HFrEF. All participants were subjected to the following: History taking, Physical examination, Serial 12-lead ECG, 2D echo to assess: -LVEDD, LVESD and LVEF%, LVEDVI (ml/m2), LVESVI (ml/m2), (LAVI) ml/m2, E/e′ ratio. 2D STE was done before and after 6 months of sacubitril/valsartan. Results Age 48 ± 9 years, 63% females, 9 (4.5%) were in NYHA FC I, 120 (60%) NYHA FC II, 64 (32%) of patients were in NYHA FC III & 7 (3.5%) were in FC IV. improved to NYHA FC I, 82 (41%) NYHA FC II 118 (59%), LVEDV, LVESV, LVEF, E/e′ were 139.3 ± 7.3, 89.7 ± 4.7, 34.9 ± 2.8, 11.2 ± 2.7, that all improved to 139.1 ± 10.5, 89.0 ± 4.4, 35.6 ± 2.6, 9.1 ± 2.3. 82 (41%) patient showed improvement in LVEF either by traditional TTE or STE, 118 (59%) patients showed no improvement of EF by traditional TTE, of them 74 (37%) patients was improved detected by STE while 44 (22%) patients showed no improvement in EF neither by TTE nor by STE. Conclusion STE is more accurate diagnostic tool for detecting early improvment in LVEF that not detected by traditional TTE in patient with HFREF treated by scubitril/valsartan. Additional Content An author video to accompany this abstract is available on https://academic.o
心衰的病理生理涉及一种适应不良反应,在此期间(RAAS)被激活。RAAS激活导致VC、HT、醛固酮水平升高、交感神经张力增加,最终导致心脏重构,所有这些都不利于疾病的进展。通过阻断这些不适应因子,acei或arb在降低HF的发病率和死亡率方面发挥了重要作用。同时,NP系统也被激活,因此在HF加重中可以看到BNP和NT-pro BNP的升高。这是一种代偿机制,可导致VD、尿钠和利尿、降低血压、降低交感神经张力和醛固酮水平。NP系统对RAAS起拮抗作用,对HF的发病机制有有利作用,NP被一种叫做neprilysin的酶分解,neprilysin抑制剂阻断其作用可以防止NP的分解,从而延长这些肽的有利作用的持续时间。Sacubitril/valsartan是一种含有neprilysin (NEP)抑制剂(Sacubitril)和(Ang-II)受体阻滞剂(valsartan)的一流药物。STE是评估心室功能的敏感工具,甚至是传统成像技术无法检测到的亚临床心肌改变。心内膜下功能主要由纵向收缩提供动力,其受损时间早于周向或径向收缩。因此,纵向功能在大多数情况下是左室功能障碍的最佳早期标志。目的本研究的目的是回顾性检测经sacubitril/ val沙坦治疗的患者是否在TTE评估的LVEF中没有改善,同一患者是否会在2D STE评估的LVEF中有改善?方法本研究纳入200例HFrEF患者。所有受试者均接受以下检查:病史记录、体格检查、连续12导联心电图、二维超声评估:-LVEDD、LVESD和LVEF%、LVEDVI (ml/m2)、LVESVI (ml/m2)、(LAVI) ml/m2、E/ E比值。在服用苏比里尔/缬沙坦6个月前后分别进行2D STE检查。结果年龄48±9岁,女性占63%,NYHA FCⅰ型9例(4.5%),NYHA FCⅱ型120例(60%),NYHA FCⅲ型64例(32%);FC iv改善为NYHA FC I 7例(3.5%),NYHA FC II改善为82例(41%),LVEDV、LVESV、LVEF、E/ E′分别为139.3±7.3、89.7±4.7、34.9±2.8、11.2±2.7,分别改善为139.1±10.5、89.0±4.4、35.6±2.6、9.1±2.3。82例(41%)患者经传统TTE或STE均可改善LVEF, 118例(59%)患者经传统TTE无改善,其中74例(37%)患者经STE检测有改善,44例(22%)患者经TTE或STE均无改善。结论STE能较传统TTE更准确地检测出经斯比普利/缬沙坦治疗的HFREF患者LVEF的早期改善情况。一个作者的视频,伴随着这个摘要可在https://academic.oup.com/eurheartjsupp。请点击“更多内容”旁边的箭头,然后点击“作者视频”。
{"title":"Does speckle tracking transthorasic echocardiography show subtle changes in left ventricular function in patient with heart failure with reduced ejection fraction treated by Sacubitril-Valsartan","authors":"Amr Setouhi, Hazem M A Farrag, Nasser M Taha, Hany T Askalany","doi":"10.1093/eurheartjsupp/suad113.004","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suad113.004","url":null,"abstract":"Abstract Introduction Pathophysiology of HF involves a maladaptive response during which the (RAAS) is activated. RAAS activation leads to VC, HT, increased aldosterone levels, increased sympathetic tone, and eventually, cardiac remodeling, all of which are detrimental to the progression of the disease. By blocking these maladaptive elements, ACEIs or ARBs play a major role in reducing morbidity and mortality due to HF, Simultaneously, the NP system is also activated, hence the elevated BNP and NT-pro BNP seen in HF exacerbations. This is a Compensatory mechanism that leads to VD, natriuresis and diuresis, lowers BP, lowers sympathetic tone, and reduces aldosterone levels. The NP system works antagonistically to the RAAS and has favorable effects on the pathogenesis of HF NP are broken down by an enzyme called neprilysin and blocking of its action by neprilysin inhibitor prevent the breakdown of NP leading to prolonged duration of the favorable effects of these peptides. Sacubitril/valsartan is a first-in-class medicine that contains a neprilysin (NEP) inhibitor (sacubitril) and (Ang-II) receptor blocker (valsartan). STE is a sensitive tool for assessing ventricular function, even subclinical myocardial alterations that traditional imaging techniques are not able to detect. Sub endocardial function is powered mostly by longitudinal contraction, it is impaired earlier than circumferential or radial component's. Therefore, Longitudinal function is in most cases the best early marker of LV dysfunction. Objective The aim of our study is to retrospectively detect if the patients treated by sacubitril/valsartan showed no improvement in LVEF assessed by TTE, is the same patient will shows improvement in LVEF assessed by 2D STE? Methods Our study will include 200 patients with HFrEF. All participants were subjected to the following: History taking, Physical examination, Serial 12-lead ECG, 2D echo to assess: -LVEDD, LVESD and LVEF%, LVEDVI (ml/m2), LVESVI (ml/m2), (LAVI) ml/m2, E/e′ ratio. 2D STE was done before and after 6 months of sacubitril/valsartan. Results Age 48 ± 9 years, 63% females, 9 (4.5%) were in NYHA FC I, 120 (60%) NYHA FC II, 64 (32%) of patients were in NYHA FC III &amp; 7 (3.5%) were in FC IV. improved to NYHA FC I, 82 (41%) NYHA FC II 118 (59%), LVEDV, LVESV, LVEF, E/e′ were 139.3 ± 7.3, 89.7 ± 4.7, 34.9 ± 2.8, 11.2 ± 2.7, that all improved to 139.1 ± 10.5, 89.0 ± 4.4, 35.6 ± 2.6, 9.1 ± 2.3. 82 (41%) patient showed improvement in LVEF either by traditional TTE or STE, 118 (59%) patients showed no improvement of EF by traditional TTE, of them 74 (37%) patients was improved detected by STE while 44 (22%) patients showed no improvement in EF neither by TTE nor by STE. Conclusion STE is more accurate diagnostic tool for detecting early improvment in LVEF that not detected by traditional TTE in patient with HFREF treated by scubitril/valsartan. Additional Content An author video to accompany this abstract is available on https://academic.o","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"120 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135299050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of myocardial injury in patients after acute ischaemic stroke according to standard criteria. 急性缺血性脑卒中后心肌损伤发生率的标准分析。
IF 1.6 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-06-01 DOI: 10.1093/eurheartjsupp/suad104
Michal Mihalovic, Petr Mikulenka, Hana Línková, Marek Neuberg, Ivana Štětkářová, Tomáš Peisker, David Lauer, Petr Tousek

This study examined the prevalence of acute and chronic myocardial injury according to standard criteria in patients after acute ischaemic stroke (AIS) and its relation to stroke severity and short-term prognosis. Between August 2020 and August 2022, 217 consecutive patients with AIS were enrolled. Plasma levels of high-sensitive cardiac troponin I (hs-cTnI) were measured in blood samples obtained at the time of admission and 24 and 48 h later. The patients were divided into three groups according to the Fourth Universal Definition of Myocardial Infarction: no injury, chronic injury, and acute injury. Twelve-lead ECGs were obtained at the time of admission, 24 and 48 h later, and on the day of hospital discharge. A standard echocardiographic examination was performed within the first 7 days of hospitalization in patients with suspected abnormalities of left ventricular function and regional wall motion. Demographic characteristics, clinical data, functional outcomes, and all-cause mortality were compared between the three groups. The National Institutes of Health Stroke Scale (NIHSS) at the time of admission and the modified Rankin Scale (mRS) 90 days following hospital discharge were used to assess stroke severity and outcome. Elevated hs-cTnI levels were measured in 59 patients (27.2%): 34 patients (15.7%) had acute myocardial injury and 25 patients (11.5%) had chronic myocardial injury within the acute phase after ischaemic stroke. An unfavourable outcome, evaluated based on the mRS at 90 days, was associated with both acute and chronic myocardial injury. Myocardial injury was also strongly associated with all-cause death, with the strongest association in patients with acute myocardial injury, at 30 days and at 90 days. Kaplan-Meier survival curves showed that all-cause mortality was significantly higher in patients with acute and chronic myocardial injury than in patients without myocardial injury (P < 0.001). Stroke severity, evaluated with the NIHSS, was also associated with acute and chronic myocardial injury. A comparison of the ECG findings between patients with and without myocardial injury showed a higher occurrence in the former of T-wave inversion, ST segment depression, and QTc prolongation. In echocardiographic analysis, a new abnormality in regional wall motion of the left ventricle was identified in six patients. Chronic and acute myocardial injury with hs-cTnI elevation after AIS are associated with stroke severity, unfavourable functional outcome, and short-term mortality.

本研究探讨急性缺血性脑卒中(AIS)患者急性和慢性心肌损伤发生率及其与脑卒中严重程度和短期预后的关系。在2020年8月至2022年8月期间,连续入组了217名AIS患者。在入院时以及24和48小时后采集的血液样本中测量高敏心肌肌钙蛋白I (hs-cTnI)的血浆水平。根据心肌梗死的第四种通用定义将患者分为三组:无损伤、慢性损伤和急性损伤。入院时、24小时、48小时及出院当天分别行12导联心电图。在怀疑左心室功能和局部壁运动异常的患者住院前7天内进行标准超声心动图检查。比较三组患者的人口学特征、临床资料、功能结局和全因死亡率。入院时采用美国国立卫生研究院卒中量表(NIHSS),出院后90天采用改良Rankin量表(mRS)评估卒中严重程度和预后。59例患者(27.2%)检测到hs-cTnI水平升高:34例患者(15.7%)有急性心肌损伤,25例患者(11.5%)在缺血性卒中后急性期有慢性心肌损伤。基于90天mRS评估的不良结果与急性和慢性心肌损伤相关。心肌损伤也与全因死亡密切相关,在30天和90天急性心肌损伤患者中相关性最强。Kaplan-Meier生存曲线显示,急性和慢性心肌损伤患者的全因死亡率明显高于无心肌损伤患者(P < 0.001)。用NIHSS评估的脑卒中严重程度也与急性和慢性心肌损伤相关。对比心肌损伤患者与非心肌损伤患者的心电图表现,前者t波倒置、ST段压低、QTc延长发生率较高。超声心动图分析发现6例患者左心室局部壁运动出现新的异常。AIS后伴有hs-cTnI升高的慢性和急性心肌损伤与卒中严重程度、不良功能结局和短期死亡率相关。
{"title":"Prevalence of myocardial injury in patients after acute ischaemic stroke according to standard criteria.","authors":"Michal Mihalovic,&nbsp;Petr Mikulenka,&nbsp;Hana Línková,&nbsp;Marek Neuberg,&nbsp;Ivana Štětkářová,&nbsp;Tomáš Peisker,&nbsp;David Lauer,&nbsp;Petr Tousek","doi":"10.1093/eurheartjsupp/suad104","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suad104","url":null,"abstract":"<p><p>This study examined the prevalence of acute and chronic myocardial injury according to standard criteria in patients after acute ischaemic stroke (AIS) and its relation to stroke severity and short-term prognosis. Between August 2020 and August 2022, 217 consecutive patients with AIS were enrolled. Plasma levels of high-sensitive cardiac troponin I (hs-cTnI) were measured in blood samples obtained at the time of admission and 24 and 48 h later. The patients were divided into three groups according to the Fourth Universal Definition of Myocardial Infarction: no injury, chronic injury, and acute injury. Twelve-lead ECGs were obtained at the time of admission, 24 and 48 h later, and on the day of hospital discharge. A standard echocardiographic examination was performed within the first 7 days of hospitalization in patients with suspected abnormalities of left ventricular function and regional wall motion. Demographic characteristics, clinical data, functional outcomes, and all-cause mortality were compared between the three groups. The National Institutes of Health Stroke Scale (NIHSS) at the time of admission and the modified Rankin Scale (mRS) 90 days following hospital discharge were used to assess stroke severity and outcome. Elevated hs-cTnI levels were measured in 59 patients (27.2%): 34 patients (15.7%) had acute myocardial injury and 25 patients (11.5%) had chronic myocardial injury within the acute phase after ischaemic stroke. An unfavourable outcome, evaluated based on the mRS at 90 days, was associated with both acute and chronic myocardial injury. Myocardial injury was also strongly associated with all-cause death, with the strongest association in patients with acute myocardial injury, at 30 days and at 90 days. Kaplan-Meier survival curves showed that all-cause mortality was significantly higher in patients with acute and chronic myocardial injury than in patients without myocardial injury (<i>P</i> < 0.001). Stroke severity, evaluated with the NIHSS, was also associated with acute and chronic myocardial injury. A comparison of the ECG findings between patients with and without myocardial injury showed a higher occurrence in the former of T-wave inversion, ST segment depression, and QTc prolongation. In echocardiographic analysis, a new abnormality in regional wall motion of the left ventricle was identified in six patients. Chronic and acute myocardial injury with hs-cTnI elevation after AIS are associated with stroke severity, unfavourable functional outcome, and short-term mortality.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"25 Suppl E","pages":"E3-E9"},"PeriodicalIF":1.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/17/45/suad104.PMC10206909.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9897475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Previous antithrombotic therapy does not have an impact on the in-hospital mortality of patients with upper gastrointestinal bleeding. 以前的抗血栓治疗对上消化道出血患者的住院死亡率没有影响。
IF 1.6 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-06-01 DOI: 10.1093/eurheartjsupp/suad103
Marek Hozman, Sabri Hassouna, Lukas Grochol, Petr Waldauf, Tomas Hracek, Blanka Zborilova Pazdiorova, Stanislav Adamec, Pavel Osmancik

The association between antithrombotics (ATs) and the risk of gastrointestinal bleeding is well known; however, data regarding the influence of ATs on outcomes are scarce. The goals of this study are: (i) to assess the impact of prior AT therapy on in-hospital and 6-month outcomes and (ii) to determine the re-initiation rate of the ATs after a bleeding event. All patients with upper gastrointestinal bleeding (UGB) who underwent urgent gastroscopy in three centres from 1 January 2019 to 31 December 2019 were retrospectively analysed. Propensity score matching (PSM) was used. Among 333 patients [60% males, mean age 69.2 (±17.3) years], 44% were receiving ATs. In multivariate logistic regression, no association between AT treatment and worse in-hospital outcomes was observed. Development of haemorrhagic shock led to worse survival [odds ratio (OR) 4.4, 95% confidence interval (CI) 1.9-10.2, P < 0.001; after PSM: OR 5.3, 95% CI 1.8-15.7, P = 0.003]. During 6-months follow-up, higher age (OR 1.0, 95% CI 1.0-1.1, P = 0.002), higher comorbidity (OR 1.4, 95% CI 1.2-1.7, P < 0.001), a history of cancer (OR 3.6, 95% CI 1.6-8.1, P < 0.001) and a history of liver cirrhosis (OR 2.2, 95% CI 1.0-4.4, P = 0.029) were associated with higher mortality. After a bleeding episode, ATs were adequately re-initiated in 73.8%. Previous AT therapy does not worsen in-hospital outcomes in after UGB. Development of haemorrhagic shock predicted poor prognosis. Higher 6-month mortality was observed in older patients, patients with more comorbidities, with liver cirrhosis and cancer.

抗血栓药物(ATs)与胃肠道出血风险之间的关联是众所周知的;然而,关于ATs对结果影响的数据很少。本研究的目的是:(i)评估先前AT治疗对住院和6个月预后的影响;(ii)确定出血事件后AT的重新启动率。回顾性分析2019年1月1日至2019年12月31日在三个中心接受紧急胃镜检查的所有上消化道出血(UGB)患者。采用倾向评分匹配(PSM)。333例患者中(60%为男性,平均年龄69.2(±17.3)岁),44%接受ATs治疗。在多变量logistic回归中,未观察到AT治疗与较差的住院预后之间的关联。发生出血性休克导致生存率降低[优势比(OR) 4.4, 95%可信区间(CI) 1.9 ~ 10.2, P < 0.001;PSM后:OR 5.3, 95% CI 1.8 ~ 15.7, P = 0.003]。在6个月的随访中,较高的年龄(OR 1.0, 95% CI 1.0-1.1, P = 0.002)、较高的合并症(OR 1.4, 95% CI 1.2-1.7, P < 0.001)、癌症史(OR 3.6, 95% CI 1.6-8.1, P < 0.001)和肝硬化史(OR 2.2, 95% CI 1.0-4.4, P = 0.029)与较高的死亡率相关。出血发作后,73.8%的患者充分重新启动了ATs。先前的AT治疗不会使UGB后的住院结果恶化。出血性休克的发生预示预后不良。老年患者、合并症较多、肝硬化和癌症患者6个月死亡率较高。
{"title":"Previous antithrombotic therapy does not have an impact on the in-hospital mortality of patients with upper gastrointestinal bleeding.","authors":"Marek Hozman,&nbsp;Sabri Hassouna,&nbsp;Lukas Grochol,&nbsp;Petr Waldauf,&nbsp;Tomas Hracek,&nbsp;Blanka Zborilova Pazdiorova,&nbsp;Stanislav Adamec,&nbsp;Pavel Osmancik","doi":"10.1093/eurheartjsupp/suad103","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suad103","url":null,"abstract":"<p><p>The association between antithrombotics (ATs) and the risk of gastrointestinal bleeding is well known; however, data regarding the influence of ATs on outcomes are scarce. The goals of this study are: (i) to assess the impact of prior AT therapy on in-hospital and 6-month outcomes and (ii) to determine the re-initiation rate of the ATs after a bleeding event. All patients with upper gastrointestinal bleeding (UGB) who underwent urgent gastroscopy in three centres from 1 January 2019 to 31 December 2019 were retrospectively analysed. Propensity score matching (PSM) was used. Among 333 patients [60% males, mean age 69.2 (±17.3) years], 44% were receiving ATs. In multivariate logistic regression, no association between AT treatment and worse in-hospital outcomes was observed. Development of haemorrhagic shock led to worse survival [odds ratio (OR) 4.4, 95% confidence interval (CI) 1.9-10.2, <i>P</i> < 0.001; after PSM: OR 5.3, 95% CI 1.8-15.7, <i>P</i> = 0.003]. During 6-months follow-up, higher age (OR 1.0, 95% CI 1.0-1.1, <i>P</i> = 0.002), higher comorbidity (OR 1.4, 95% CI 1.2-1.7, <i>P</i> < 0.001), a history of cancer (OR 3.6, 95% CI 1.6-8.1, <i>P</i> < 0.001) and a history of liver cirrhosis (OR 2.2, 95% CI 1.0-4.4, <i>P</i> = 0.029) were associated with higher mortality. After a bleeding episode, ATs were adequately re-initiated in 73.8%. Previous AT therapy does not worsen in-hospital outcomes in after UGB. Development of haemorrhagic shock predicted poor prognosis. Higher 6-month mortality was observed in older patients, patients with more comorbidities, with liver cirrhosis and cancer.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"25 Suppl E","pages":"E25-E32"},"PeriodicalIF":1.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/07/80/suad103.PMC10206644.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9897481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Left bundle branch area pacing results in more physiological ventricular activation than biventricular pacing in patients with left bundle branch block heart failure. 左束支区域起搏比双心室起搏在左束支阻断心衰患者中引起更多的生理性心室激活。
IF 1.6 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-06-01 DOI: 10.1093/eurheartjsupp/suad109
Ondrej Sussenbek, Leonard Rademakers, Petr Waldauf, Pavel Jurak, Radovan Smisek, Petr Stros, Lukas Poviser, Jana Vesela, Filip Plesinger, Josef Halamek, Pavel Leinveber, Dalibor Herman, Pavel Osmancik, Karol Curila

Biventricular pacing (Biv) and left bundle branch area pacing (LBBAP) are methods of cardiac resynchronization therapy (CRT). Currently, little is known about how they differ in terms of ventricular activation. This study compared ventricular activation patterns in left bundle branch block (LBBB) heart failure patients using an ultra-high-frequency electrocardiography (UHF-ECG). This was a retrospective analysis including 80 CRT patients from two centres. UHF-ECG data were obtained during LBBB, LBBAP, and Biv. Left bundle branch area pacing patients were divided into non-selective left bundle branch pacing (NSLBBP) or left ventricular septal pacing (LVSP) and into groups with V6 R-wave peak times (V6RWPT) < 90 ms and ≥ 90 ms. Calculated parameters were: e-DYS (time difference between the first and last activation in V1-V8 leads) and Vdmean (average of V1-V8 local depolarization durations). In LBBB patients (n = 80) indicated for CRT, spontaneous rhythms were compared with Biv (39) and LBBAP rhythms (64). Although both Biv and LBBAP significantly reduced QRS duration (QRSd) compared with LBBB (from 172 to 148 and 152 ms, respectively, both P < 0.001), the difference between them was not significant (P = 0.2). Left bundle branch area pacing led to shorter e-DYS (24 ms) than Biv (33 ms; P = 0.008) and shorter Vdmean (53 vs. 59 ms; P = 0.003). No differences in QRSd, e-DYS, or Vdmean were found between NSLBBP, LVSP, and LBBAP with paced V6RWPTs < 90 and ≥ 90 ms. Both Biv CRT and LBBAP significantly reduce ventricular dyssynchrony in CRT patients with LBBB. Left bundle branch area pacing is associated with more physiological ventricular activation.

双心室起搏(Biv)和左束支区起搏(LBBAP)是心脏再同步化治疗(CRT)的两种方法。目前,人们对它们在心室激活方面的差异知之甚少。本研究使用超高频心电图(UHF-ECG)比较左束支传导阻滞(LBBB)心衰患者的心室激活模式。这是一项回顾性分析,包括来自两个中心的80例CRT患者。在LBBB、LBBAP和Biv期间获得UHF-ECG数据。将左束支区起搏患者分为非选择性左束支起搏(NSLBBP)和左室间隔起搏(LVSP)两组,分别分为V6 r波峰值时间(V6RWPT) < 90 ms和≥90 ms两组。计算参数为:e-DYS (V1-V8导联第一次和最后一次激活的时间差)和Vdmean (V1-V8局部去极化持续时间的平均值)。LBBB患者(n = 80)接受CRT,与Biv节律(39)和LBBAP节律(64)进行比较。尽管与LBBB相比,Biv和LBBAP均显著缩短了QRS持续时间(QRSd)(分别从172 ms降至148 ms和152 ms, P均< 0.001),但两者之间差异不显著(P = 0.2)。左束分支区域起搏导致e-DYS (24 ms)短于Biv (33 ms);P = 0.008)和更短的Vdmean (53 vs. 59 ms;P = 0.003)。NSLBBP、LVSP和LBBAP在V6RWPTs < 90 ms和≥90 ms时的QRSd、e-DYS或Vdmean均无差异。Biv CRT和LBBAP均可显著降低LBBB患者的心室非同步化。左束支区起搏与更多的生理性心室激活有关。
{"title":"Left bundle branch area pacing results in more physiological ventricular activation than biventricular pacing in patients with left bundle branch block heart failure.","authors":"Ondrej Sussenbek,&nbsp;Leonard Rademakers,&nbsp;Petr Waldauf,&nbsp;Pavel Jurak,&nbsp;Radovan Smisek,&nbsp;Petr Stros,&nbsp;Lukas Poviser,&nbsp;Jana Vesela,&nbsp;Filip Plesinger,&nbsp;Josef Halamek,&nbsp;Pavel Leinveber,&nbsp;Dalibor Herman,&nbsp;Pavel Osmancik,&nbsp;Karol Curila","doi":"10.1093/eurheartjsupp/suad109","DOIUrl":"https://doi.org/10.1093/eurheartjsupp/suad109","url":null,"abstract":"<p><p>Biventricular pacing (Biv) and left bundle branch area pacing (LBBAP) are methods of cardiac resynchronization therapy (CRT). Currently, little is known about how they differ in terms of ventricular activation. This study compared ventricular activation patterns in left bundle branch block (LBBB) heart failure patients using an ultra-high-frequency electrocardiography (UHF-ECG). This was a retrospective analysis including 80 CRT patients from two centres. UHF-ECG data were obtained during LBBB, LBBAP, and Biv. Left bundle branch area pacing patients were divided into non-selective left bundle branch pacing (NSLBBP) or left ventricular septal pacing (LVSP) and into groups with V6 R-wave peak times (V6RWPT) < 90 ms and ≥ 90 ms. Calculated parameters were: e-DYS (time difference between the first and last activation in V1-V8 leads) and Vdmean (average of V1-V8 local depolarization durations). In LBBB patients (<i>n</i> = 80) indicated for CRT, spontaneous rhythms were compared with Biv (39) and LBBAP rhythms (64). Although both Biv and LBBAP significantly reduced QRS duration (QRSd) compared with LBBB (from 172 to 148 and 152 ms, respectively, both <i>P</i> < 0.001), the difference between them was not significant (<i>P</i> = 0.2). Left bundle branch area pacing led to shorter e-DYS (24 ms) than Biv (33 ms; <i>P</i> = 0.008) and shorter Vdmean (53 vs. 59 ms; <i>P</i> = 0.003). No differences in QRSd, e-DYS, or Vdmean were found between NSLBBP, LVSP, and LBBAP with paced V6RWPTs < 90 and ≥ 90 ms. Both Biv CRT and LBBAP significantly reduce ventricular dyssynchrony in CRT patients with LBBB. Left bundle branch area pacing is associated with more physiological ventricular activation.</p>","PeriodicalId":11956,"journal":{"name":"European Heart Journal Supplements","volume":"25 Suppl E","pages":"E17-E24"},"PeriodicalIF":1.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c0/a3/suad109.PMC10206755.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9897483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
European Heart Journal Supplements
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1